Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014; 371:1619-28.
 Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72.
 Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015; 372:1312-23.
 David N, George M, Henry F, et al. The Sanford Guide to Antimicrobial Therapy 2018. Virginia: ANTIMICROBIAL THERAPY, INC., 2018.
 Segev S, Raz R, Rubinstein E, et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur J Clin Microbiol Infect Dis. 1995; 14:851-5.
 de Klerk GJ, van Steijn JH, Lobatto S, et al. A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections. Int J Antimicrob Agents. 1999; 12:121-7.
 Dietrich ES, Joseph U, Vogel F, et al. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany. Infection. 1999; 27:148-54.
 Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis. 1995; 171:356-61.
 Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44(2):159-77.
 Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008; 32:139-46.
 World Health Organization. Ageing and life-course. World report on ageing and health. http://www.who.int/ageing/publications/world-report-2015/en. Accessed 2 June 2019.
 Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63:e61-e111.
 Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: A multicenter prospective study. PLoS One. 2015; 10: e0122247.
 Van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations. J Stat Softw. 2011; 45:1–67.
 Sekhon J. Multivariate and propensity score matching. J Stat Softw. 2011; 42:52.
 Shiraishi A, Kushimoto S, Otomo Y, et al. Effectiveness of early administration of tranexamic acid in patients with severe trauma. Br J Surg. 2017; 104:710-717.
 Opatowski L, Mandel J, Varon E, et al. Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics. Antimicrob Agents Chemother. 2010; 54:2330-7.
 Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015; 15:161-71.
 Lodise TP, Anzueto AR, Weber DJ, et al. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials. Antimicrob Agents Chemother. 2015; 59:1119-26.
 Althunian TA, de Boer A, Klungel OH, et al. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials. 2017; 18:107.
 Shalviri G, Yousefian S, Gholami K. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre. J Clin Pharm Ther. 2012; 37:448-51.
 Lopez AJ, O'Keefe P, Morrissey M, et al. Ceftriaxone-induced cholelithiasis. Annals of Internal Medicine. 1991; 115:712-4.
 Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58:377-82.
 Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336:243-50.
 Adamuz J, Viasus D, Jiménez-Martínez E, et al. Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. J Infect. 2014; 68:534-41.
 Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013; 68:1057-65.
 Shindo Y, Ito R, Kobayashi D, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis. 2015; 15:1055-1065.